Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$182.34 USD

182.34
1,025,151

-2.45 (-1.33%)

Updated Jun 17, 2026 04:00 PM ET

After-Market: $182.38 +0.04 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 247)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of +24.80% and +5.01%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organon (OGN) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Organon (OGN) delivered earnings and revenue surprises of +6.38% and +2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate AMN Healthcare Services (AMN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Charles River Q2 Earnings Preview: What's in Store for the Stock?

by Zacks Equity Research

CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.

Zacks Equity Research

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Is it Prudent to Retain Charles River Stock in Your Portfolio Now?

by Zacks Equity Research

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Zacks Equity Research

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Charles River Stock May Gain From Extended CHDI Research Deal on HD

by Zacks Equity Research

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Zacks Equity Research

Should You Continue to Hold Charles River Stock in Your Portfolio?

by Zacks Equity Research

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.